![]() ![]() The Popular Sovereignty Doctrineĭuring his time in Congress, Douglas became known as a gifted debater and key supporter of westward expansion and the principle of popular sovereignty.ĭouglas sponsored the Kansas-Nebraska Act, passed by Congress in 1854, which, in allowing the Kansas and Nebraska territories (today’s Kansas, Nebraska, Montana, North Dakota and South Dakota) to choose whether or not to allow slavery, served as a repeal of the 1820 Missouri Compromise, which banned slavery in northern territories. senator.ĭouglas ran unsuccessfully for president of the United States on the Democratic ticket in 1852, 18. From 1847 until his death in 1861, he served three terms as a U.S. House of Representatives, a seat he held for three terms until 1847. He was appointed Illinois secretary of state during the 1840-41 legislative session and elected to serve as a judge on the Illinois Supreme Court in 1841. In 1836, Douglas was elected to the Illinois General Assembly, serving as a Democrat. Douglas briefly courted Mary Todd, who went on to marry his future rival, Abraham Lincoln. ).In New York, Douglas clerked at a law firm, then moved to Cleveland, where he continued to study law before moving to Illinois in 1833, at age 20, where he worked as a schoolmaster before earning a law license in 1834 and setting up a law practice in Jacksonville, about 35 miles west of the state Capitol.ĭid you know? After moving to Illinois in the 1830s, Stephen A. (Funded by Sanofi and Regeneron Pharmaceuticals ODYSSEY OUTCOMES number, NCT01663402. 2.1% in the placebo group).Īmong patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo. The incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions (3.8% in the alirocumab group vs. ![]() The absolute benefit of alirocumab with respect to the composite primary end point was greater among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter than among patients who had a lower baseline level. A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died (hazard ratio, 0.85 95% CI, 0.73 to 0.98). A composite primary end-point event occurred in 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85 95% confidence interval, 0.78 to 0.93 P<0.001). The median duration of follow-up was 2.8 years. The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non-high-density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |